1228555-64-3

Upstream product

• 1228555-63-2 C₁₄H₁₁NO₅ 

Downstream Products

• 1300040-38-3 4-hydroxy-2-oxo-6-((R)-phenyl((R)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoyloxy) methyl)-1,2-dihydropyridine-3-carboxylic acid 
• 1300040-37-2 4-hydroxy-2-oxo-6-((S)-phenyl((R)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoyloxy) methyl)-1,2-dihydropyridine-3-carboxylic acid 
• 1300040-42-9 (R)-4-hydroxy-6-(hydroxy(phenyl)methyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid 
• 1300040-41-8 (S)-4-hydroxy-6-(hydroxy(phenyl)methyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid 
• 1303531-29-4 (R)-(-)-4-hydroxy-6-((3-methylbutanoyloxy)(phenyl)methyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid 
• 663891-81-4 (S)-(+)-4-hydroxy-6-((3-methylbutanoyloxy)(phenyl)methyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid 
• 1228648-54-1 4-hydroxy-6-((3-methylbutanoyloxy)(phenyl)methyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid 

Relevant academic research and scientific papers

The first total synthesis of potent human chymase inhibitor SPF32629B via regioselective bromination and O-acylation strategy

An efficient total synthesis of (±)-SPF32629B is described. The key features of the synthesis include regioselective bromination followed by carboxylation at C-3 and protecting-group-free regioselective acylation of hydroxyl group present at C7. Structure